The University of Cincinnati Cancer Center’s Blood Cancer Healing Center added research laboratories and the UC Osher Wellness Suite and Learning Kitchen. The expansion joins clinical services launched in July 2024 and adds new research, wellness and community programming space.
The FDA is set to make decisions on four drug applications in April 2026, including Orca-T for hematological malignancies, orforglipron for obesity, sparsentan for kidney disease, and a doravirine/islatravir combination for HIV-1.
Faron Pharmaceuticals announces Phase II BEAM-X trial evaluating bexmarilimab plus azacitidine in MRD-positive AML patients after stem cell transplantation. The Nordic AML Group-led trial will enroll 24 patients with first results expected 12-15 months after enrollment begins in Q3 2026.
Calidi Biotherapeutics presented preclinical data on its RedTail virotherapy platform at the 2026 AACR Immuno-Oncology conference, demonstrating tumor-localized BiTE expression and IL-15 superagonist delivery. The company plans to submit an IND application for CLD-401 by end of 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07541326 |
Complementary and Alternative Medicine Among Patients With Hematologic Malignancies in France |
NOT_YET_RECRUITING | NA |
| NCT07539779 |
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07456982 |
The Effect of Relaxation Breathing Exercise on Chemotherapy Induced Nausea and Vomiting |
ACTIVE_NOT_RECRUITING | NA |
| NCT07362732 |
Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07362602 |
Exploratory Study on in Vivo CAR-T Therapy Targeting CD20 for the Treatment of Hematological Malignancies |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07220616 |
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies |
RECRUITING | PHASE1/PHASE2 |
| NCT07137481 |
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies |
NOT_YET_RECRUITING | PHASE2 |
| NCT07122674 |
18F-Pentixafor PET in Hematologic Malignancies |
RECRUITING | |
| NCT07071909 |
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells |
WITHDRAWN | PHASE1/PHASE2 |
| NCT07047352 |
Prospective Study Evaluate the Timing of Empirical Treatment for Carbapenem-resistant Bacterials (CROEAT Study) |
NOT_YET_RECRUITING | NA |
